Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) saw a significant drop in short interest in September. As of September 15th, there was short interest totalling 467,200 shares, a drop of 70.2% from the August 31st total of 1,570,000 shares. Based on an average daily volume of 20,860,000 shares, the short-interest ratio is currently 0.0 days. Currently, 0.3% of the company’s stock are sold short.
Tonix Pharmaceuticals Stock Up 1.3 %
NASDAQ TNXP traded up $0.00 during trading hours on Wednesday, reaching $0.13. 1,219,386 shares of the company were exchanged, compared to its average volume of 7,506,082. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.72 and a current ratio of 1.15. The business’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $3.30. Tonix Pharmaceuticals has a 1 year low of $0.13 and a 1 year high of $26.56.
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last posted its earnings results on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing the consensus estimate of ($9.91) by ($9.37). The business had revenue of $2.21 million during the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. On average, equities research analysts predict that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on Tonix Pharmaceuticals
Hedge Funds Weigh In On Tonix Pharmaceuticals
An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 260.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent quarter. 82.26% of the stock is currently owned by hedge funds and other institutional investors.
Tonix Pharmaceuticals Company Profile
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Stories
- Five stocks we like better than Tonix Pharmaceuticals
- Insider Trades May Not Tell You What You Think
- Analyst Think There’s Still Time to Get in on Edgewise, Up 332%
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Stocks Raising Dividends 4X Higher Than Inflation
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Palantir Stock Joins the S&P 500; Is It Time to Buy?
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.